TRIPLE NEGATIVE BREAST CANCER (TNBC)
Clinical trials for TRIPLE NEGATIVE BREAST CANCER (TNBC) explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST CANCER (TNBC) trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets Cancer's 'Extra DNA' in desperate patients
Disease control OngoingThis early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of cancer-driving genes. The goal is to find a safe dose and see if BBI-355, alone or with other ta…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
Promising combo aims to stop triple negative breast cancer from coming back
Disease control OngoingThis study tests whether a combination of two chemotherapy drugs, liposomal doxorubicin and carboplatin, given after surgery can lower the chance of cancer returning in people with early-stage triple negative breast cancer. About 30 participants will receive the treatment and be …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Mridula George, MD • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New combo shows promise against tough breast cancer
Disease control OngoingThis study tests a new drug called onvansertib combined with standard chemotherapy (paclitaxel) in people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating to see if the combination is safe and c…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Antonio Giordano, MD • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New drug AB598 takes first steps against advanced cancers
Disease control OngoingThis early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors like lung, bladder, or ovarian cancer. The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control ENROLLING_BY_INVITATIONThis study tests a new drug called RNDO-564, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like lung, bladder, or breast cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if t…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Rondo Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Engineered immune cells take on Hard-to-Treat breast cancer
Disease control OngoingThis early-stage study tests a new two-part treatment for people with advanced breast cancer that has stopped responding to standard therapies. Participants receive a single infusion of their own engineered immune cells (CLBR001) followed by cycles of an antibody drug (ABBV-461).…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Gene therapy patients monitored for years in new safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows about 400 adults who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The main goal is to track long-term safety and see how well the treatment effects last over time. Participants do not receive ne…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 03:20 UTC
-
Can exercise boost energy metabolism in Triple-Negative breast cancer patients?
Knowledge-focused OngoingThis study looks at how the body uses energy (metabolic flexibility) in women with early triple-negative breast cancer. Researchers will track changes at diagnosis, after chemo, after surgery, and after a 12-week exercise program. The goal is to see which type of exercise—moderat…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: NA • Sponsor: Universidad Europea de Madrid • Aim: Knowledge-focused
Last updated May 26, 2026 03:10 UTC